Webinars/Presentations

Learn from the best in industry

Webinars and Presentations

rakesh-nagarajan.jpg

November 29, 2018

Supporting NGS-Based In Vitro Diagnostics: A Clinical Genomics Knowledge Sharing and Inferencing Approach

guests: Rakesh Nagarajan, MD, PhD

host: Josh Forsythe

To support comprehensive interpretation of in vitro diagnostic assays, PierianDx has developed a robust approach for genomics knowledge sharing and inferencing. Driven by a rich set of curated and rationalized content of medical interpretations, clinical practice guidelines, FDA therapeutics and clinical trials, this approach provides well-vetted interpretations and classifications of genomic variants for in vitro diagnostics.  

Register
PierianDx Webinar: IVD KB.jpg
Shalini Small.jpg

October 31, 2018

Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

guests: Shalini Verma, MD, FCAP 

host: Association for Molecular Pathology Annual Meeting, 2018

Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. In this informative workshop, we review the guidelines developed by the Association for Molecular Pathology (AMP) and describe how to put them into practice using real clinical cases.

Download Slides
AMP Guidelines for the Interpretation and Reporting.png
rakesh-nagarajan-486268-edited.jpg

October 31, 2018

Supporting NGS-based IVD Assays with the Most Accurate, Comprehensive, and Clinically Robust Knowledgebase

guests: Rakesh Nagarajan, MD, PhD

host: Association for Molecular Pathology Annual Meeting, 2018

Clinical NGS has been widely adopted as Laboratory Derived Tests (LDTs). NGS-based in vitro diagnostics (IVD) recently gained FDA approval with many others now in process. These IVD assays facilitate broad, widespread adoption of NGS-based testing globally in cancer and other complex conditions that require timely, accurate diagnoses and treatment. To support comprehensive interpretation of these assays, we have developed the PierianDx KnowledgeBase. Driven by the richest set of curated and rationalized content of medical interpretations, clinical practice guidelines, FDA therapeutics and clinical trials, the PierianDx KnowledgeBase offers the most well-vetted interpretations and classifications of genomic variants for IVD use.

Download Slides
AMP Supporting NGS-based IVD Assays.png
Shalini_200x200.jpg
karl-200717-edited.jpg

August 28, 2018

CAP Distributive Model of NGS Testing: A Rapid, Economical Approach to Building Your NGS Program

guests: Shalini Verma, MD, FCAP; and Karl Voelkerding, MD, FCAP

host: Rakesh Nagarjan, MD, PhD

Optimism for next generation sequencing (NGS) technologies to be used in a clinical setting quickly turns to numerous conversations about the challenges involved. In this webinar, we discuss the CAP (College of American Pathologists) Distributive Model and how your organization can leverage it to rapidly and economically conduct or scale clinical NGS testing.

View Webinar
2018-08-14_12-54-57.png
Andy-Bredemeyer-PierianDx-499202-edited.jpg
Shalini_200x200.jpg

July 19, 2018

A Practice-based Guide to Interpretation and Reporting of Sequence Variants in Cancer

guests: Shalini Verma, MD, FCAP; Andy Bredemeyer, PhD

host: Josh Forsythe

Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. Guidelines developed by the Association for Molecular Pathology (AMP) with representation from key institutions, including ACMG, outline a system to categorize sequence variations in cancer.

View Webinar
Interpretation-Webinar-Cover-Image.png
eric loo.jpeg
rakesh-nagarajan-752925-edited.jpg

May 31, 2018

Bringing NGS Testing In-House

guests: Eric Loo, MD and Rakesh Nagarjan, MD, PhD

host: Josh Forsythe

Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savingsIn-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.

View Webinar
Header-Image-636w.png
webinar-628971-edited.jpeg

February 22, 2018

Panel Discussion Regarding Debated CMS National Coverage Decision on NGS Testing

guests:  Ravindra Kolhe, MD, PhD; Karen L. Kaul, MD, PhD; Theresa Ann Boyle, MD, PhD; Mani S. Mahadevan, MD; and Nikoletta Sidiropoulos, MD

hosts: Rakesh Nagarjan, MD, PhD, and Shalini Verma, MD,FCAP

How do recent coverage decisions on NGS testing affect you? For academic centers, leading cancer institutions, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.

View Webinar
CMS Roundtable.png
webinar-628971-edited.jpeg

October 12, 2017

Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling

guests: Gregory Tsongalis, MD; Anthony Magliocco, MD; and Ravindra Kolhe, MD

hosts: GenomeWeb and PierianDx

The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability. Panelists discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.

View Webinar
NGS Tumor Profiling.png
rakesh-nagarajan.jpg

January 21th, 2017

Clinical Genomics Workspace (CGW): Accelerate Your NGS Testing with an End-to-End Integrated Workspace

guest: Rakesh Nagarajan

host: PierianDx

PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out.

View Webinar
CGW-Screenshot-Laptop.png
tony.jpg

September 14, 2017

Building a Best-in-Class Precision Medicine Program: The Moffitt Cancer Center Story

guest: Anthony Magliocco, MD

host: Rakesh Nagarajan, MD, PhD

Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.

View Webinar
Moffitt Webinar.png
rakesh-nagarajan.jpg

July 13, 2017

Taking Your NGS Testing Program to the Next Level with Enhanced Validation and Interpretation Services

guest: Rakesh Nagarajan

host: PierianDx

The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput.

View Webinar
Next level NGS.png
Niki Sidiropoulos-625306-edited.jpg

March 9, 2017

Accelerating Your NGS Testing Program: Examples and Case Studies

guest: Nikoletta Sidiropoulos, MD

host: PierianDx

Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.

View Webinar
Strategic Approach to NGS.png
webinar-628971-edited.jpeg

December 21th, 2022

NGS Roundtable: Ask the Experts about the Future of Clinical NGS Testing

guests: Allie Grossman, MD; Karl Voelkerding, MD, FCAP; and Rakesh Nagarajan, MD, PhD

host: GenomeWeb

This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.

View Webinar
Future of NGS Roundtable.png
Andy-Bredemeyer-PierianDx-499202-edited.jpg

January 12, 2017

Practice Guidelines and Clinical Trials in CGW

guest:  Andy Bredemeyer, PhD

host: PierianDx

Learn more about the knowledgebase and how PierianDx annotates practice guidelines and clinical trials.

 

View Webinar
CGW-Screenshot-Laptop.png

Not Seeing a Topic?

Contact us to provide feedback on webinar topics you want us to cover.
Suggest Webinar